MBP 3.23% 3.0¢ metabolic pharmaceuticals limited

improved market sentiment

  1. 58 Posts.
    “Chemgenix, Heartware, Metabolic and
    Pharmaxis among the top picks for 06/07”
    (Radar Investor Relations survey of
    16 leading biotech analysts)

    “Metabolic Pharmaceutical’s impressive
    (Bioshares, 13 Oct 2006)

    “MBP is a very different company than it was
    two years ago…the product line has been
    significantly expanded”
    (ABN-AMRO Morgans’ weekly
    healthcare newsletter, 17 Oct 2006)

    “Metabolic was a "screaming bargain at 45c"
    … a "super-binary" company that seems set
    to go well if the Phase 2 trial results are
    (Patersons analyst Dr Matthijs
    Smith quoted in Biotechnology
    News, 20 October 2006)

watchlist Created with Sketch. Add MBP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.